Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

UniTao Pharma Puts Planned US Facility on Hold

publication date: Mar 23, 2015
UniTao Pharmaceuticals has idled plans to open a US manufacturing plant in Petersburg, Virginia, where it was expected to make APIs for the ex-China market. The company cited adverse business conditions for the setback, though it did not provide details. In October 2014, UniTao, a division of China's Tenry Pharma, announced it would invest $22.5 million to buy and refurbish a Boehringer Ingelheim facility that was about to be shut down. Apparently, UniTao paid $2.4 million to acquire the plant, but decided to postpone any updates.  More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital